Skip to main content
Loading

Challenges of using single domain antibodies as new modalities of multifunctional biologics

23 Sep 2024
Sonoma
Formats & Scaffolds
  • Stability and Manufacturing: While sdAbs offer high stability and solubility, optimizing large-scale production without compromising their unique properties can be a challenge.
  • Target Specificity and Efficacy: Ensuring sdAbs maintain high specificity across multiple targets, while integrating them into complex multifunctional biologics, raises potential efficacy and off-target concerns.
  • Immune Response and Toxicity: As new modalities, understanding and mitigating potential immunogenicity or toxicity in vivo remains crucial for therapeutic safety and success.
Industry Expert
Shaun Lippow, Head of Biologics - Remunix, Inc.